Testosterone deficiency: a risk factor for heart failure
Source: Testosterone deficiency in male: a risk factor for heart failure. Giagulli VA, Guastamacchia E, De Pergola G, et al. Endocr Metab Immune Disord Drug Targets 2013;13:92–9.
A reduction in circulating testosterone levels may contribute to specific features of CHF such as fatigue, weakness, shortness of breath, weight loss and deterioration in physical condition. Testosterone therapy is often used to treat men with TDS, and recent evidence suggests that Testosterone therapy may improve muscle strength and lung capacity in patients with CHF, especially those with TDS. However, large clinical trials are required to assess the long-term effectiveness and safety of Testosterone therapy in these patients.